Patients with HIV and AIDS exhibit higher risk for HPV-related noncervical cancers

Patients with HIV and AIDS exhibit an increased risk of developing human papillomavirus (HPV)-related noncervical cancers, particularly anal cancer, according to study findings published in Open Forum Infectious Diseases.

Although HPV vaccination is a critical preventive strategy, global coverage remains low. Prior studies have mainly focused on cervical cancer, but the impact of HIV on HPV-related cancers at other anatomical sites is less well understood. Therefore, researchers conducted a systematic review, meta-analysis, and modeling study to estimate the global burden of noncervical cancers attributable to HIV and to assess the potential benefits of expanded HPV vaccine coverage.

The researchers systematically searched multiple databases, identifying 25 studies with a combined population of 1,560,923 patients with HIV and AIDS. The analysis included cases of anal, vaginal, vulvar, penile, and oropharyngeal cancers, with risk ratios (RRs) compared against HIV-negative populations. Data from UNAIDS on HIV prevalence, the International Agency for Research on Cancer’s global cancer registry, and World Health Organization vaccine coverage statistics were used to estimate the attributable cancer burden and model vaccine impact.

Pooled results showed a significantly increased risk for HPV-related noncervical cancers among patients with HIV and AIDS, including anal cancer (RR, 30.32; 95% CI, 20.54-44.75), vaginal cancer (RR, 15.78; 95% CI, 4.62-53.92), vulvar cancer (RR, 6.99; 95% CI, 3.37-14.51), penile cancer (RR, 6.37; 95% CI, 3.98-10.21), and oropharyngeal cancer (RR, 2.74; 95% CI, 2.10-3.58). Geographically, the burden was highest in Africa, where HIV accounted for up to 30% of cases compared with just 5% worldwide.

Modeling estimates suggested that at current vaccine coverage levels, 3384 noncervical cancer cases are prevented annually among patients with HIV and AIDS. However, if HPV vaccine coverage increased to 90% globally, more than twice as many cases could be prevented (7462 annually at 90% efficacy). Even with conservative assumptions of 50% efficacy, 1987 additional cases could be averted.

The researchers highlighted ongoing challenges such as limited resources, unequal vaccine access, and reduced coverage post-COVID-19. They stressed that integrating HPV vaccination with HIV services could boost coverage and efficiency, especially in low- and middle-income countries with high HIV prevalence.

Study limitations included reliance on observational data, heterogeneity among studies, and underrepresentation of low-resource settings in the available literature.